Ann: DyeVert featured at the SCAI 2020 Scientific Session, page-5

Gazza the definition to me is also a little unclear in context to the study (refer below) however absolute
is a defined value or result and I would take relative
as being in context to previous records or statistics.

The announcement is as interesting as it is exciting. 2 case studies from 2 hospitals, one refered directly in the announcement and with the other case study having 1789 patients out of 1956 studied being a large sample set and both during an approximate period Q1 2018 to Q3 2019. (refer below)


Some google numbers to go by:
-Cardiac Catheter Labs USA 2119 (IMV census 2014)
- >1 million diagnostic cardiac catheterizations
(excluding percutaneous coronary
intervention–only procedures) performed in the USA (CHEST 2018)

Patients who would be in consideration for Dyevert Contrast Dye monitoring would depend on their risk score and general health eg. Pre existing kidney issues, diabetes etc. But from the announced studies what % of those >1m treatments can we approximate require DyeVert intervention?

However it is looked at, there is a clear need for the device to deliver better patient health and outcomes, clearly from the studies the reporting timeline is slow however continued appraisals and hospital procedure, peer reviews will see uptake continue to climb and potentially greater with EU markets via GE should a distribution deal be concluded in the coming months.

All imo DYOR.

Keep well cheers Paul